Dexcom makes glucose monitoring systems for patients with diabetes. I don't see Americans getting healthier any time soon, so demand for the company's products should remain high for the foreseeable future.
The stock is just breaking out of a high tight flag pattern. Technically, a high tight flag requires a move up of 100% or more, so DXCM comes up a little short on the initial surge. But the pullback inside the flag was very shallow - well below the 25% allowed in this setup. So for me, it balances out.
On the fundamental side, sales growth is accelerating. +23%, +25%, and +32% for the last three quarters. Earnings are also expected to jump by 40% in 2022.
The stop loss on this trade would be the just beneath the low of the flag at $487.00.
The stock is just breaking out of a high tight flag pattern. Technically, a high tight flag requires a move up of 100% or more, so DXCM comes up a little short on the initial surge. But the pullback inside the flag was very shallow - well below the 25% allowed in this setup. So for me, it balances out.
On the fundamental side, sales growth is accelerating. +23%, +25%, and +32% for the last three quarters. Earnings are also expected to jump by 40% in 2022.
The stop loss on this trade would be the just beneath the low of the flag at $487.00.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.